An accompanying research for the Phase II study of nivolumab + bevacizumab + paclitaxel in patients with HER2-negative metastatic breast cancer:WJOG9917B(WJOG9917BTR)

Conditions

HER2-negative metastatic breast cancer

Yukinori Ozaki, Shigehisa Kitano, Kazuma Kiyotani, Makiko Yamashita, Lifang Wang et al. (18 authors)

Clinical Cancer Research2025-06-13

Abstract P5-02-42: Soluble CD163 may be a predictive biomarker of the efficacy of nivolumab plus chemotherapy in patients with HER2-negative metastatic breast cancer (WJOG9917BTR)

Toru Mukohara, Yukinori Ozaki, Shigehisa Kitano, Makiko Yamashita, Daiki Ikarashi et al. (16 authors)

Cancer Research2023-03-011 citations

10.1158/1538-7445.sabcs22-p5-02-42

Abstract PS4-14: Immunological analysis of the combination therapy of nivolumab, paclitaxel and bevacizumab in patients with HER2-negative MBC in NEWBEAT trial (WJOG9917BTR)

Yukinori Ozaki, Shigehisa Kitano, Junji Tsurutani, Tsutomu Iwasa, Masato Takahashi et al. (14 authors)

Cancer Research2021-02-151 citations

10.1158/1538-7445.sabcs20-ps4-14

Abstract OT1-12-02: Biomarker study of patients with HER2-negative metastatic breast cancer receiving combination therapy with nivolumab, bevacizumab and paclitaxel as first-line treatment (WJOG9917BTR)

Yukinori Ozaki, S Kitano, Koichiro Matsumoto, Masashi Takahashi, Toru Mukohara et al. (11 authors)

Cancer Research2019-02-152 citations

10.1158/1538-7445.sabcs18-ot1-12-02

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients who agreed to this study (WJOG9917BTR) among those who participated in WJOG9917B trial

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Immune-related biomarker of nivolumab in combination with paclitaxel and bevacizumab	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results